Objective: To describe clinical findings and survival times for dogs with functional thyroid tumors treated with surgery alone and investigate potential prognostic factors for outcome in these patients.
Animals: 27 client-owned dogs.
Procedures: Medical records of 9 institutions were reviewed to identify dogs with hyperthyroidism secondary to thyroid neoplasia that were treated with surgery alone between 2005 and 2015. Data collected included signalment, hematologic and physical examination findings, tumor staging results, time from diagnosis to treatment, surgical procedure performed, histologic findings, evidence of recurrence or metastatic disease, and date of death or last follow-up. Median survival time and 1-, 2-, and 3-year survival rates were assessed by Kaplan-Meier analysis. Associations between variables of interest and the outcome of death were assessed with Cox proportional hazards models.
Results: Dogs from 8 institutions met inclusion criteria. Median age at diagnosis was 10 years (range, 8 to 13 years). Golden Retrievers and Labrador Retrievers were commonly represented (5 dogs each). Polyuria with polydipsia (15/27 [56%]) and weight loss (12 [44%]) were the most common clinical signs; 2 dogs without clinical signs had hyperthyroidism identified by routine hematologic analysis. One dog had metastatic disease at the time of diagnosis. Most tumors (23/27 [85%]) were malignant. Estimated median survival time was 1,072 days. No significant prognostic factors were identified.
Conclusions And Clinical Relevance: Dogs with resectable functional thyroid tumors had a good prognosis with surgical excision alone. Survival times for these dogs were similar to those in previous studies that included dogs with nonfunctional thyroid tumors.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.2460/javma.256.4.444 | DOI Listing |
J Clin Transl Endocrinol
December 2024
Department of Medical and Surgical Sciences (DIMEC), University of Bologna, 40138 Bologna, Italy.
Thanks to the identification of crucial molecular pathways, the therapeutic landscape for advanced differentiated thyroid tumors (DTCs) has significantly improved during the last ten years. The therapeutic scenario has been greatly impacted by the discovery of mutually exclusive gene changes in the MAPK and PI3K/AKT pathways, such as or fusions and pathogenic mutations of the and genes. Indeed, multi-kinase inhibitors and selective inhibitors have demonstrated outstanding efficacy for radioactive iodine-refractory (RAI-R) drug treatment, with overall response rates reaching up to 86%.
View Article and Find Full Text PDFFront Endocrinol (Lausanne)
January 2025
Center of Breast and Thyroid Surgery, Department of General Surgery, The Third People's Hospital of Chengdu, Chengdu, Sichuan, China.
Objective: This study aimed to assess the degree of effect of central lymph node dissection on postoperative hypoparathyroidism incidence.
Methods: The incidence of postoperative hypoparathyroidism was compared between patients receiving thyroidectomy with central neck dissection for papillary thyroid carcinoma and those undergoing thyroidectomy for benign thyroid diseases (thyroid follicular adenoma and/or nodular goiter) necessitating surgical intervention.
Results: The incidence of postoperative hypoparathyroidism was not significantly different between the groups of lobe thyroidectomy for benign thyroid diseases and lobe thyroidectomy with ipsilateral central lymph node dissection for papillary thyroid carcinoma (immediate: 9.
Front Immunol
January 2025
Department of Medical Oncology, Harbin Medical University Cancer Hospital, Harbin, China.
Introduction: The relationship between immune-related thyroid dysfunction (irTD) and survival rates in cancer patients remains unclear. Furthermore, the impact of variations in immunotherapy line numbers and pathological types among lung cancer patients on this relationship has not been fully elucidated. This study aims to evaluate the potential of irTD as a prognostic marker for immunotherapy in Chinese patients with lung cancer.
View Article and Find Full Text PDFSmall
January 2025
Key Laboratory of Biorheological Science and Technology, Ministry of Education, College of Bioengineering, Chongqing University, No. 174 Shazheng Road, Chongqing, 400044, China.
Direct electrochemical detection of miRNA biomarkers in tumor tissue interstitial fluid (TIF) holds great promise for adjuvant therapy for tumors in the perioperative period, yet is limited by background interference and weak signal. Herein, a wash-free and separation-free miRNA biosensor based on photoexcited electro-driven reactive oxygen channeling analysis (LEOCA) is developed to solve the high-fidelity detection in physiological samples. In the presence of miRNA, nanoacceptors (ultrasmall-size polydopamine, uPDA) are responsively assembled on the surface of nanodonors (zirconium metal-organic framework, ZrMOF) to form core-satellite aggregates.
View Article and Find Full Text PDFCell Commun Signal
January 2025
School of Medicine, Southeast University, Nanjing, Jiangsu, China.
Tribbles homolog 2 (TRIB2), a pseudoserine/threonine kinase, is a member of the TRIB family. TRIB2 primarily regulates cell proliferation through its scaffold or adaptor effect on promoting the degradation of target proteins by E3 ligase-dependent ubiquitination and regulating mitogen-activated protein kinase (MAPK) and protein kinase B (AKT) signaling pathways. TRIB2 is not only involved in the physiological proliferation of cells (granulosa cells, myoblasts, naive T cells, and thymocytes) during normal development but also in the pathological proliferation of vascular smooth muscle cells and a variety of cancer cells (lung cancer cells, liver cancer cells, leukemia cells, pancreatic cancer cells, gastric cancer cells, prostate cancer cells, thyroid cancer cells, cervical cancer cells, melanoma cells, colorectal cancer cells, ovarian cancer cells and osteosarcoma cells) under disease conditions.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!